Imlygic
Phase 1Small molecule
Imlygic is one of 9 small molecule programs targeting Fibroma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Fibroma
#DrugCompanyPhaseTrials
1Rapamune
PPrism Pharmaceuticals
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Voltaren
CCerimon Pharmaceuticals
Phase 2
Oncovin
EEastern Cooperative Oncology Group
Phase 2
Levulan
BBiomed Industries, Inc.
Phase 2
"celecoxib", "celebrex"
EEsteve Pharmaceuticals, S.A.
Phase 2
Peg-Interferon Alpha-2b
Merck & Co.Phase 2
Kybella
AbbViePhase 1
Imlygic
JJohns Hopkins University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Imlygic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJohns Hopkins University